North American Biopharma — Decision Effectiveness
A North American biopharma, cutting the drift between what the committee decided and what the organisation actually did.
Context
A North American biopharma whose committee decisions were sound at the moment they were taken, and reliably drifted in execution. Each quarter closed with the honest observation that half of what had been decided had not happened as decided.
Challenge
The decisions were disappearing somewhere between the committee minutes and the operating teams. Nobody was blocking them — but nobody was being held accountable for shipping them either.
Approach
We instituted a decision ledger: every committee outcome logged with a single named owner, a date-bounded first checkpoint, and a visible status that could not be hidden in a quarterly update. Every subsequent committee meeting opened by walking the ledger.
The ledger was deliberately low-tech. The point was not tooling; the point was that no decision could quietly die.
What shifted
Decision mortality dropped sharply. The committee started making fewer decisions, because each one now cost real follow-through. The ones it made landed.
What shifted: decisions got cheaper to make and more expensive to abandon.
Client identity anonymised. Specific metrics available under NDA.